Omeros Corporation
OMER Healthcare Biotechnology
In the quarter to June 2026, revenue grew 35.5%, EPS grew 141.9%, free cash flow grew 118.7% and total debt fell 42.0%, each against the same quarter a year earlier.
Follow OMER
Omeros Corporation (OMER) Altman Z-score
Omeros Corporation's Altman Z-score for fiscal 2018 is −10.72, in the distress zone (below 1.81).
Altman Z-score, annual
Embed this chart
Annual newest first
| Period | Altman Z-score | Change (points) |
|---|---|---|
| FY2020 | −6.82 | 1.27 |
| FY2019 | −8.09 | 2.64 |
| FY2018 | −10.72 | (9.04) |
| FY2017 | −1.68 | 7.05 |
| FY2016 | −8.73 | 2.08 |
| FY2015 | −10.82 | — |
How fiscal 2018’s score is made up
| Component | This year | Year before | Result | Points |
|---|---|---|---|---|
| Working capital / total assets | 0.55 | — | 0.66 | |
| Retained earnings / total assets | (6.78) | — | −9.49 | |
| EBIT / total assets | (1.17) | — | −3.86 | |
| Market value of equity / total liabilities | 2.76 | — | 1.66 | |
| Sales / total assets | 0.31 | — | 0.31 | |
| Altman Z-score | Distress zone | −10.72 | ||
| Z″ Variant for non-manufacturing and asset-light companies (drops the sales/assets term, uses book equity) | Distress zone | −26.90 | ||
How the Altman Z-score works
Z = 1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets (Altman, 1968). The market value of equity is the close on the last trading day of the fiscal year times weighted basic shares.
Z″ = 6.56 × working capital ÷ total assets + 3.26 × retained earnings ÷ total assets + 6.72 × EBIT ÷ total assets + 1.05 × book equity ÷ total liabilities (Altman, Hartzell and Peck, 1995), the variant for non-manufacturing and asset-light companies.
| Zone | Z | Z″ |
|---|---|---|
| Safe zone | above 2.99 | above 2.60 |
| Grey zone | 1.81–2.99 | 1.10–2.60 |
| Distress zone | below 1.81 | below 1.10 |
Not worked out for banks, insurers and REITs, whose balance sheets the model does not describe, nor when a figure is missing or there is no share price in the week to the fiscal year end.
Altman Z-score against peers
| Company | Altman Z-score |
|---|---|
| ANAB AnaptysBio, Inc. compare | 0.8× |
| AAPG Ascentage Pharma Group International - Unsponsored ADR compare | 0.8× |
| INBX Inhibrx Biosciences, Inc. compare | 0.7× |
| OMER Omeros Corporation | −6.8× |
| NKTR Nektar Therapeutics compare | −17.1× |
| GHRS GH Research PLC compare | — |
| TYRA Tyra Biosciences, Inc. compare | — |
| ORIC Oric Pharmaceuticals, Inc. compare | — |
| RAPP Rapport Therapeutics, Inc. compare | — |
What Altman Z-score is
The Altman Z-Score weighs working capital, retained earnings, operating profit, market value and sales against assets and debts to gauge the risk of distress.
1.2 × working capital ÷ total assets + 1.4 × retained earnings ÷ total assets + 3.3 × EBIT ÷ total assets + 0.6 × market value of equity ÷ total liabilities + 1.0 × revenue ÷ total assets